PUBLIC COMPANY
saveNovo Nordisk Inc
updated 2mo ago
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares.
community read0 votes
🐶 often sniffed alongside
top 8- tagApproval78 co-mentions · 39 sources
- drugVICTOZA59 co-mentions · 30 sources
- drugLIRAGLUTIDE30 co-mentions · 30 sources
- drugSaxenda30 co-mentions · 30 sources
- drugOzempic23 co-mentions · 4 sources
- drugWegovy23 co-mentions · 4 sources
- drugWegovy Pill22 co-mentions · 3 sources
- drugSOGROYA18 co-mentions · 9 sources
pipeline
16
marketed
15
phase 3
0
catalysts ytd
4
approvals ytd
3
recalls ytd
0
Pipeline(16)
view full pipeline →pipeline depth16 products
15Marketed1Unknown
Marketed
(estradiol + norethindrone)
Atrophic Vaginitis (Vaginal Atrophy/Vulvovaginal Atrophy/…
Marketed(insulin aspart + insulin aspart protamine)
Type 1 Diabetes (Juvenile Diabetes)
Marketed(insulin degludec + liraglutide)
Type 2 Diabetes
Marketed(insulin human + insulin isophane)
Type 1 Diabetes (Juvenile Diabetes)
MarketedFiasp
Type 1 Diabetes (Juvenile Diabetes)
MarketedRybelsus
Cardiovascular Risk Factors
MarketedSaxenda
Obesity
MarketedWegovy Pill
type 2 diabetes, cardiovascular risk reduction
Marketedcoagulation factor IX (recombinant), glycopegylated LA
Hemophilia B (Factor IX Deficiency)
Marketedcoagulation factor XIII A-subunit (recombinant)
Fibrin Stabilizing Factor Deficiency (Factor XIII Deficie…
Marketedconcizumab
Hemophilia A (Factor VIII Deficiency)
Marketeddasiglucagon
Hypoglycemia
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?Despite coming away with an early victory over Eli Lilly in the oral obesity face-off, analysts don’t expect Novo Nordisk’s lead to last for very long.biospace · 6h ago
- EMD Serono cuts 20 at Massachusetts research siteFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 20h ago
- Amylyx’s bet on a GLP-1 blocker pays offA late-stage trial found the drug, which Amylyx bought for cheap in a bankruptcy auction, was effective at regulating blood sugar in patients who’d just undergone bariatric surgery.biopharma_dive · 23h ago
- Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemiaWith a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year.…biospace · 23h ago
- STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and moreAstraZeneca is discontinuing a late-stage drug trial in patients with metastatic non-small cell lung cancer, extending a run of setbacksstat · 1d ago
- Baylor Genetics hit by cybersecurity attack targeting patient, staff informationDiagnostic genomics company Baylor Genetics has become the latest victim of a life sciences cybersecurity breach, with both patients and employees affected.fiercebiotech · 2d ago
- Skye and Redx form new entity with $125M to advance fibrosis assetsSkye Bioscience has entered into an agreement to combine with privately held fibrotic disease biotech Redx Pharma in a deal that will net $125 million in financing for the new public company, calle…fiercebiotech · 4d ago
- Chutes & Ladders—Former Legend CEO lands at K2Just weeks after Legend Biotech announced the departure of its CEO, Ying Huang, K2 Therapeutics has announced that Wang will now lead the startup, which was founded in 2024 with a $50 million seed…fiercebiotech · 5d ago
- STAT+: Pharmalittle: We’re reading about California insulin sales, a Moderna patent battle, and moreSeven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 eachstat · 5d ago
- Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutideAhead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.biopharma_dive · 6d ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that